Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of fluid and electrolyte depletion,Provision of caloric intake in patients requiring parenteral nutrition,Correction of hypoglycemia,Maintenance fluid therapy
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Dextrose: <15 minutes due to rapid cellular uptake and metabolism; sodium and chloride: no defined half-life as electrolytes are homeostatically regulated.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose is rapidly metabolized via glycolysis and the Krebs cycle; sodium chloride is not metabolized but excreted renally.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal; dextrose is metabolized to CO2 and water; sodium and chloride are excreted renally with >90% reabsorption under normal conditions.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: negligible; sodium and chloride: not protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose: approximately 0.2 L/kg (total body water); sodium and chloride: distribute into extracellular fluid (approx 0.2 L/kg).
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
100% for intravenous route; not applicable for oral/other routes.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustment for dextrose; monitor fluid and electrolyte balance. In severe renal impairment (e GFR <30 m L/min/1.73 m²), restrict volume as needed to avoid fluid overload and hyperkalemia when combined with sodium chloride.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific adjustment for Child-Pugh class; monitor glucose and fluid status. Caution in severe hepatic failure due to risk of hyperglycemia and fluid retention.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based dosing: Intravenous infusion at 4-8 mg/kg/min for glucose provision; typical maintenance fluid rates: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for each additional kg. Individualize based on age, weight, and clinical status.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Monitor for fluid overload, hyperglycemia, and electrolyte disturbances. Use lower initial infusion rates (e.g., 50-100 m L/hour) and adjust based on renal function and cardiovascular status. Avoid excessive sodium load in patients with hypertension or heart failure.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Not for use in patients with intracranial or intraspinal hemorrhage, or in those with known hypersensitivity to corn or corn products (dextrose source).
None
Risk of hyperglycemia, especially in diabetic patients,Risk of fluid overload, especially in patients with renal impairment or heart failure,Electrolyte imbalances (e.g., hypernatremia, hyperchloremia) with excessive administration,Use with caution in patients with hepatic disease, as dextrose may exacerbate encephalopathy
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia,Hypernatremia,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe hypokalemia (can worsen with dextrose infusion)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. However, as this solution provides dextrose (sugar) and sodium, patients with diabetes or salt-restricted diets should be monitored. Avoid concurrent intake of high-sugar or high-salt foods without medical advice.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglycemia-related congenital anomalies. Intravenous administration may be necessary in third trimester for fluid maintenance. No direct fetal toxicity.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Dextrose and sodium chloride are normal constituents of breast milk. Intravenous infusion does not alter milk composition significantly. M/P ratio not applicable. Considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dosing adjustment required solely for pregnancy. However, increased plasma volume in pregnancy may require careful monitoring of fluid balance to avoid overload. Adjust rate and volume based on clinical status, not pregnancy per se.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Use with caution in patients with congestive heart failure, renal impairment, or conditions causing sodium retention. Monitor serum glucose and electrolytes, especially in diabetic patients or those receiving parenteral nutrition. Avoid in patients with hyperglycemia, hyponatremia, or fluid overload. Do not administer simultaneously with blood products due to risk of hemolysis. Inspect for particulate matter and discoloration before use; discard if present.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Inform your healthcare provider if you have diabetes, high blood pressure, heart or kidney disease, or fluid retention.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing.,Tell your doctor if you experience headache, confusion, muscle cramps, or swelling of hands/ankles.,This solution provides sugar and salt; discuss any dietary restrictions with your doctor.,Do not use the solution if it is cloudy, discolored, or contains particles.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglyc. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.